We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lipid-lowering Therapy for Secondary Prevention in Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01190072
First Posted: August 27, 2010
Last Update Posted: January 29, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
August 26, 2010
August 27, 2010
January 29, 2013
September 2010
March 2011   (Final data collection date for primary outcome measure)
  • Serum total cholesterol concentration [ Time Frame: Week 0 ]
  • Serum total cholesterol concentration [ Time Frame: Once during the time period between Week 6 and Week 10 ]
  • Serum LDL cholesterol concentration [ Time Frame: Week 0 ]
  • Serum LDL cholesterol concentration [ Time Frame: Once during the time period between Week 6 and Week 10 ]
  • Serum total cholesterol concentration [ Time Frame: Week 0 ]
  • Serum total cholesterol concentration [ Time Frame: Week 6 ]
  • Serum total cholesterol concentration [ Time Frame: Week 7 ]
  • Serum total cholesterol concentration [ Time Frame: Week 8 ]
  • Serum total cholesterol concentration [ Time Frame: Week 9 ]
  • Serum total cholesterol concentration [ Time Frame: Week 10 ]
  • Serum LDL cholesterol concentration [ Time Frame: Week 0 ]
  • Serum LDL cholesterol concentration [ Time Frame: Week 6 ]
  • Serum LDL cholesterol concentration [ Time Frame: Week 7 ]
  • Serum LDL cholesterol concentration [ Time Frame: Week 8 ]
  • Serum LDL cholesterol concentration [ Time Frame: Week 9 ]
  • Serum LDL cholesterol concentration [ Time Frame: Week 10 ]
Complete list of historical versions of study NCT01190072 on ClinicalTrials.gov Archive Site
  • Proportion of patients achieving LDL-C < 2 mmol/L [ Time Frame: Once during the time period between Week 6 and Week 10 ]
  • Proportion of patients achieving total cholesterol < 4 mmol/L [ Time Frame: Once during the time period between Week 6 and Week 10 ]
  • Change of hsCRP levels from baseline [ Time Frame: Once during the time period between Week 6 and Week 10 ]
  • Proportion of patients achieving LDL-C < 2 mmol/L [ Time Frame: Week 6 ]
  • Proportion of patients achieving LDL-C < 2 mmol/L [ Time Frame: Week 7 ]
  • Proportion of patients achieving LDL-C < 2 mmol/L [ Time Frame: Week 8 ]
  • Proportion of patients achieving LDL-C < 2 mmol/L [ Time Frame: Week 9 ]
  • Proportion of patients achieving LDL-C < 2 mmol/L [ Time Frame: Week 10 ]
  • Proportion of patients achieving total cholesterol < 4 mmol/L [ Time Frame: Week 6 ]
  • Proportion of patients achieving total cholesterol < 4 mmol/L [ Time Frame: Week 7 ]
  • Proportion of patients achieving total cholesterol < 4 mmol/L [ Time Frame: Week 8 ]
  • Proportion of patients achieving total cholesterol < 4 mmol/L [ Time Frame: Week 9 ]
  • Proportion of patients achieving total cholesterol < 4 mmol/L [ Time Frame: Week 10 ]
  • Change of hsCRP levels from baseline [ Time Frame: Week 6 ]
  • Change of hsCRP levels from baseline [ Time Frame: Week 7 ]
  • Change of hsCRP levels from baseline [ Time Frame: Week 8 ]
  • Change of hsCRP levels from baseline [ Time Frame: Week 9 ]
  • Change of hsCRP levels from baseline [ Time Frame: Week 10 ]
Not Provided
Not Provided
 
Lipid-lowering Therapy for Secondary Prevention in Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)
LIPID-LOWERING THERAPY FOR SECONDARY PREVENTION IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) A 10-week, Open-label, Non-interventional Study of Total Cholesterol/LDL-cholesterol Management in Real Life in Coronary Patients Hospitalised for Elective PCI
The purpose of the study is to follow the management of blood lipids in patients with planned percutaneous coronary intervention (widening of coronary vessels) in a period from 6 to 10 weeks after the intervention.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Secondary care clinic
Coronary Artery Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
120
March 2011
March 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or nonpregnant female
  • Coronary patient hospitalised for elective PCI
  • Hypercholesterolaemia defined as LDL-C ≥ 2 mmol/L

Exclusion Criteria:

  • Any chronic inflammatory condition
  • Chronic anti-inflammatory pharmacotherapy (except low-dose ASA)
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Slovenia
 
 
NCT01190072
NIS-CSI-DUM-2010/1
No
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Vojko Kanic University Clinical Centre, Maribor
AstraZeneca
January 2013